The estimated Net Worth of Matthew Thompson is at least $163 Tysiąc dollars as of 12 August 2020. Matthew Thompson owns over 21,888 units of Vivos Therapeutics stock worth over $160,749 and over the last 7 years Matthew sold VVOS stock worth over $1,970.
Sign up
Matthew Thompson VVOS stock SEC Form 4 insiders trading
Matthew has made over 1 trades of the Vivos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Matthew sold 21,888 units of VVOS stock worth $1,970 on 12 August 2020.
The largest trade Matthew's ever made was selling 21,888 units of Vivos Therapeutics stock on 12 August 2020 worth over $1,970. On average, Matthew trades about 1,684 units every 0 days since 2018. As of 12 August 2020 Matthew still owns at least 52,878 units of Vivos Therapeutics stock.
You can see the complete history of Matthew Thompson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Matthew Thompson's mailing address?
Matthew's mailing address filed with the SEC is 2, Musick, Irvine Spectrum, Irvine, Orange, California, 92618, United States of America.
Insiders trading at Vivos Therapeutics
Over the last 4 years, insiders at Vivos Therapeutics have traded over $0 worth of Vivos Therapeutics stock and bought 88,521 units worth $136,211 . The most active insiders traders include Anja B Krammer, Ronald Kirk Huntsman oraz Bradford K. Amman. On average, Vivos Therapeutics executives and independent directors trade stock every 77 days with the average trade being worth of $22,426. The most recent stock trade was executed by Ronald Kirk Huntsman on 20 June 2023, trading 14,000 units of VVOS stock currently worth $7,420.
What does Vivos Therapeutics do?
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
What does Vivos Therapeutics's logo look like?
Complete history of Matthew Thompson stock trades at Endologix i Vivos Therapeutics
Vivos Therapeutics executives and stock owners
Vivos Therapeutics executives and other stock owners filed with the SEC include:
-
R. Kirk Huntsman,
Co-Founder, Chairman & CEO -
Dr. Gurdev Dave Singh D.M.D., Ph.D.,
Founder, Chief Medical Officer & Director -
Bradford K. Amman,
CFO, Treasurer & Sec. -
Ruth Hembree,
Sr. VP -
Nicholas M. DeGennaro,
Sr. VP of the Medical Integration Division -
David Bryan Ferre,
Sr. VP of Marketing -
Cathryn H. Bonar,
Chief Compliance Officer and Sr. VP of Compliance & Medical Billing -
Edward A. Loew,
Chief Strategy Officer, Sr. VP of Strategy & Investor Relations Officer -
Susan McCullough,
Co-Founder & Sr. VP of Operations -
RaeAnn Byrnes,
Co-Founder and Sr. VP of People, Training & Devel. -
Todd Huntsman,
Co-Founder & Sr. VP of Manufacturing -
Bradford K. Amman,
Chief Financial Officer -
Leonard J Sokolow,
Director -
Anja B Krammer,
Director -
Ralph Elias Green,
Director -
Mark F. Lindsay,
Director -
Gurdev Dave Singh,
Chief Medical Officer -
Matthew Thompson,
Director -
Ronald Kirk Huntsman,
Chief Executive Officer